Xcout IntelSign inSubscribe

Lighthouse Pharma competitors & alternatives

Drug DiscoveryUnited States

The 12 closest competitors and alternatives to Lighthouse Pharma among drug discovery companies — ranked by similarity to what Lighthouse Pharma actually does, not by market-cap band.

12Competitors listed

Subscribe to see Lighthouse Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Lighthouse Pharma

Lighthouse Pharma is a clinical-stage private biopharmaceutical company that specializes in precision medicine approaches targeting major unmet medical needs. The company is headquartered at the Buck Institute for Research on Aging in California.

Lighthouse Pharma at a glance

Lighthouse Pharma is a drug discovery company headquartered in United States. It has raised at least $61.2M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $12M in April 2026. Xcout tracks 1 named person at Lighthouse Pharma, including Casey Lynch (Chief Executive Officer).

Lighthouse Pharma leadership

  • Casey LynchChief Executive Officer

Lighthouse Pharma funding rounds

At least $61.2M raised across the 2 rounds on record. Every round on record:

DateRoundAmountInvestors
Series A$12M1 named
Series A$49.2M1 named

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Top 12 Lighthouse Pharma competitors

Ranked by semantic similarity — how close each company is to Lighthouse Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

BridgeBio Pharma, Inc.BBIO · BiopharmaceuticalsPalo Alto, United States
65% matchPublicAI 34/100Green 2/100

Biopharmaceuticals

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Market cap$13.3B
Employees999
SpringGCPPython
BridgeBio Pharma, Inc. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Lighthouse Pharma and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Lighthouse Pharmaand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →